

# Table of Contents

Abstract .....	1
Zusammenfassung .....	2
Table of Contents .....	4
1. Introduction .....	7
1.1. Biology of B cells .....	7
1.1.1. Development of B cells .....	7
1.1.2. B cell activation and humoral immune response .....	7
1.2. Biology of plasma cells .....	8
1.2.1. Genetical networks control development of plasma cells .....	9
1.2.2. Unique mechanisms controlling plasma cell regulation .....	11
1.2.3. Maintenance of plasma cell homeostasis .....	19
1.2.4. Determinants of plasma cell longevity .....	21
1.2.5. Plasma cells in autoimmune diseases .....	22
1.2.6. Targeting plasma cells in autoimmune diseases .....	23
1.3. CRISPR/Cas gene-editing tool .....	25
1.3.1. Functional mechanism of CRISPR/Cas9 gene-editing tool .....	26
1.3.2. Delivery of CRISPR/Cas9 components into cells of interest .....	27
1.3.3. Use of CRISPR/Cas9 gene-editing tool in plasma cell research .....	28
2. Research aims .....	29
3. Materials & Methods .....	31
3.1. Materials .....	31
3.1.1. Antibodies .....	31
3.1.2. Bacterial and virus strains .....	33
3.1.3. Biological samples .....	33
3.1.4. Chemicals, peptides, and recombinant proteins .....	33
3.1.5. Commercial kits and assays .....	34
3.1.6. Cell lines .....	35
3.1.7. Oligonucleotides .....	35
3.1.8. Recombinant DNA .....	37
3.1.9. Other materials .....	38
3.1.10. Devices and instruments .....	39
3.2. Methods .....	41
3.2.1. Isolation of human peripheral blood mononuclear cells, naive B cell culture, and <i>in vitro</i> plasma cell differentiation .....	41
3.2.2. Isolation of human bone marrow mononuclear cells .....	42

3.2.3. Cell line culture .....	42
3.2.4. Plasmid construction .....	43
3.2.5. Retrovirus production and transduction .....	43
3.2.6. Flow cytometry analysis and cell sorting .....	44
3.2.7. Genomic DNA extraction.....	45
3.2.8. Polymerase chain reaction, amplicon purification, and DNA sequencing.....	45
3.2.9. T7 endonuclease I assay .....	46
3.2.10. Insertion-deletion sequence analysis .....	46
3.2.11. Data analysis and statistics .....	46
4. Results .....	47
4.1. RD114-pseudotyped retrovirus proficiently deliver genetic materials into primary human B cells .....	47
4.1.1. RD114-pseudotyped retroviral vectors excel in transduction of primary human B cells.....	47
4.1.2. <i>In vitro</i> activation with CD40L multimers fosters susceptibility of primary human B cells to RD114-pseudotyped retroviral transduction.....	49
4.2. CRISPR/Cas9 retroviral vectors are capable of introducing proficient gene knockout in primary human B cells for identifying PC regulators <i>in vitro</i> .....	51
4.2.1. Retroviral vectors introduce efficient CRISPR/Cas9-mediated knockout at DNA and protein levels in primary human B cells <i>in vitro</i> .....	51
4.2.2. Single targeting of <i>IRF4</i> , <i>PRDM1</i> , and <i>XBP1</i> impairs human plasma cell differentiation.....	54
4.3. CRISPR/Cas9-based screening reveals novel plasma cell regulators .....	58
4.3.1. Upregulation of a transcriptional program, RNA-binding proteins, Ras superfamily members, and unfolded protein response genes in human plasmablasts/plasma cells compared to memory B cells .....	58
4.3.2. CRISPR/Cas9-based screening identifies novel genes important for human plasma cell differentiation .....	60
4.4. SYVN1 as a candidate for plasma cell targeting therapies .....	63
4.4.1. Knockout of <i>SYVN1</i> in primary human B cells reduced plasma cell differentiation .	63
4.4.2. <i>In vitro</i> plasmablasts, <i>ex vivo</i> peripheral plasmablasts, and bone marrow plasma cells highly express SYVN1 .....	65
4.4.3. <i>In vitro</i> plasma cell differentiation is hindered by SYVN1 inhibitor .....	68
4.4.4. Human B cells overexpressing SYVN1 rapidly differentiate into plasma cells <i>in vitro</i>	71
5. Discussion.....	74
5.1. RD114-pseudotyped retroviral vector is highly efficient for delivering transgenic materials into primary human B cells .....	74
5.2. Retrovirus-based CRISPR/Cas9 system allows highly efficient mutagenesis in primary human B cells and identifying plasma cell regulators.....	75

---

5.3. CRISPR/Cas9 screening uncovers potential regulatory pathways of human plasma cell differentiation and targets for plasma cell-targeting therapeutics .....	76
5.4. SYVN1 as potential target for plasma cell treatment.....	80
5.5. Proposed regulatory mechanism of SYVN1 on human plasma cell differentiation .....	81
5.6. Conclusion and outlook.....	83
6. References.....	84
7. List of figures.....	102
8. List of tables .....	104
9. List of Abbreviations .....	105
10. Acknowledgements .....	109
11. Appendix .....	111